세계의 소화기 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

The global demand for Gastrointestinal Therapeutics Market is presumed to reach the market size of nearly USD 80.38 BN by 2030 from USD 48.86 BN in 2022 with a CAGR of 6.42% under the study period 2023 - 2030.

Gastrointestinal therapeutics treats gastrointestinal disorders, which are digestive system issues affecting the colon, small and large intestines, and rectum. This chronic inflammatory illness of the gastrointestinal tract mainly affects the colon's mucosal lining. Constipation, peptic ulcer diseases, and irritable bowel syndrome are the most common conditions, with symptoms such as discomfort, bloating, diarrhoea, nausea, and vomiting. Gastrointestinal therapeutics include commercially accessible medication such as Aciphex, Afinitor, akynzeo, deficit, and Prilosec.

Market Dynamics:

The rising prevalence of gastrointestinal disorders is also raising demand for gastrointestinal therapeutics to enhance better healthcare access, to change lifestyles, and for higher rates of industrialization and sanitation, which will increase the market growth. Numerous R&D organizations are investigating new therapeutic modalities, which are anticipated to boost the market expansion of gastrointestinal therapeutics. The market for gastrointestinal therapeutics is expanding due to more clinical studies with reliable outcomes and rising healthcare expenditure. The ageing population is growing, which will accelerate market expansion because they are more prone to such health problems. However, the market expansion of gastrointestinal therapeutics can be hampered by related side effects of therapies and medication and strict governmental restrictions for drug approval.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gastrointestinal therapeutics. The growth and trends of gastrointestinal therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the gastrointestinal therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Branded
• Generics

By Drug Class

• Aminosalicylates
• Digestive Enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-Emetics
• H2 Antagonists
• Anti-Diarrheal
• Biologics/Biosimilar
• Others

By Route Of Administration

• Oral
• Injectable
• Others

By Application

• Crohn'S Disease
• Ulcerative Colitis
• Gerd
• IBS
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Gastrointestinal Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gastrointestinal therapeutics market include AbbVie Inc., AstraZeneca, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals, Pfizer Inc., Bayer AG, Abbott, Cipla Inc., Gilead Sciences Inc., Biogen, Organon Group of Companies. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . GASTROINTESTINAL THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Route Of Administration
  • 3.7.4 Market Attractiveness Analysis By Application
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET ANALYSIS BY TYPE

• 6.1 Overview by Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Type
• 6.4 Branded Historic and Forecast Sales by Regions
• 6.5 Generics Historic and Forecast Sales by Regions

7 . GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

• 7.1 Overview by Drug Class
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Drug Class
• 7.4 Aminosalicylates Historic and Forecast Sales by Regions
• 7.5 Digestive Enzymes Historic and Forecast Sales by Regions
• 7.6 Proton Pump Inhibitors Historic and Forecast Sales by Regions
• 7.7 Laxatives Historic and Forecast Sales by Regions
• 7.8 Anti-Emetics Historic and Forecast Sales by Regions
• 7.9 H2 Antagonists Historic and Forecast Sales by Regions
• 7.10. Anti-Diarrheal Historic and Forecast Sales by Regions
• 7.11 Biologics/Biosimilar Historic and Forecast Sales by Regions
• 7.12 Others Historic and Forecast Sales by Regions

8 . GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 8.1 Overview by Route Of Administration
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Route Of Administration
• 8.4 Oral Historic and Forecast Sales by Regions
• 8.5 Injectable Historic and Forecast Sales by Regions
• 8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET ANALYSIS BY APPLICATION

• 9.1 Overview by Application
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Application
• 9.4 Crohn's Disease Historic and Forecast Sales by Regions
• 9.5 Ulcerative Colitis Historic and Forecast Sales by Regions
• 9.6 GERD Historic and Forecast Sales by Regions
• 9.7 IBS Historic and Forecast Sales by Regions
• 9.8 Others Historic and Forecast Sales by Regions

10 . GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 10.1 Overview by Distribution Channel
• 10.2 Historical and Forecast Data
• 10.3 Analysis by Distribution Channel
• 10.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 10.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 10.6 Online Pharmacies Historic and Forecast Sales by Regions

11 . GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 11.1. Top Company Share Analysis
• 11.2. Introduction
• 11.3. North America Sales Analysis
  • 11.3.1. Overview, Historic and Forecast Sales Analysis
  • 11.3.2. North America By Segment Sales Analysis
  • 11.3.3. North America By Country Sales Analysis
  • 11.3.4. United State Sales Analysis
  • 11.3.5. Canada Sales Analysis
  • 11.3.6. Mexico Sales Analysis
• 11.4. Europe Sales Analysis
  • 11.4.1. Overview, Historic and Forecast Sales Analysis
  • 11.4.2. Europe by Segment Sales Analysis
  • 11.4.3. Europe by Country Sales Analysis
  • 11.4.4. United Kingdom Sales Analysis
  • 11.4.5. France Sales Analysis
  • 11.4.6. Germany Sales Analysis
  • 11.4.7. Italy Sales Analysis
  • 11.4.8. Russia Sales Analysis
  • 11.4.9. Rest Of Europe Sales Analysis
• 11.5. Asia Pacific Sales Analysis
  • 11.5.1. Overview, Historic and Forecast Sales Analysis
  • 11.5.2. Asia Pacific by Segment Sales Analysis
  • 11.5.3. Asia Pacific by Country Sales Analysis
  • 11.5.4. China Sales Analysis
  • 11.5.5. India Sales Analysis
  • 11.5.6. Japan Sales Analysis
  • 11.5.7. South Korea Sales Analysis
  • 11.5.8. Australia Sales Analysis
  • 11.5.9. Rest Of Asia Pacific Sales Analysis
• 11.6. Latin America Sales Analysis
  • 11.6.1. Overview, Historic and Forecast Sales Analysis
  • 11.6.2. Latin America by Segment Sales Analysis
  • 11.6.3. Latin America by Country Sales Analysis
  • 11.6.4. Brazil Sales Analysis
  • 11.6.5. Argentina Sales Analysis
  • 11.6.6. Peru Sales Analysis
  • 11.6.7. Chile Sales Analysis
  • 11.6.8. Rest of Latin America Sales Analysis
• 11.7. Middle East & Africa Sales Analysis
  • 11.7.1. Overview, Historic and Forecast Sales Analysis
  • 11.7.2. Middle East & Africa by Segment Sales Analysis
  • 11.7.3. Middle East & Africa by Country Sales Analysis
  • 11.7.4. Saudi Arabia Sales Analysis
  • 11.7.5. UAE Sales Analysis
  • 11.7.6. Israel Sales Analysis
  • 11.7.7. South Africa Sales Analysis
  • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE GASTROINTESTINAL THERAPEUTICS COMPANIES

• 12.1. Gastrointestinal Therapeutics Market Competition
• 12.2. Partnership/Collaboration/Agreement
• 12.3. Merger And Acquisitions
• 12.4. New Product Launch
• 12.5. Other Developments

13 . COMPANY PROFILES OF GASTROINTESTINAL THERAPEUTICS INDUSTRY

• 13.1. Company Share Analysis
• 13.2. Market Concentration Rate
• 13.3. AbbVie Inc.
  • 13.3.1. Company Overview
  • 13.3.2. Company Revenue
  • 13.3.3. Products
  • 13.3.4. Recent Developments
• 13.4. AstraZeneca
  • 13.4.1. Company Overview
  • 13.4.2. Company Revenue
  • 13.4.3. Products
  • 13.4.4. Recent Developments
• 13.5. Janssen Pharmaceuticals NV
  • 13.5.1. Company Overview
  • 13.5.2. Company Revenue
  • 13.5.3. Products
  • 13.5.4. Recent Developments
• 13.6. Sun Pharmaceutical Industries Ltd.
  • 13.6.1. Company Overview
  • 13.6.2. Company Revenue
  • 13.6.3. Products
  • 13.6.4. Recent Developments
• 13.7. Takeda Pharmaceutical Company Limited
  • 13.7.1. Company Overview
  • 13.7.2. Company Revenue
  • 13.7.3. Products
  • 13.7.4. Recent Developments
• 13.8. Salix Pharmaceuticals
  • 13.8.1. Company Overview
  • 13.8.2. Company Revenue
  • 13.8.3. Products
  • 13.8.4. Recent Developments
• 13.9. Pfizer Inc.
  • 13.9.1. Company Overview
  • 13.9.2. Company Revenue
  • 13.9.3. Products
  • 13.9.4. Recent Developments
• 13.10. Bayer AG
  • 13.10.1. Company Overview
  • 13.10.2. Company Revenue
  • 13.10.3. Products
  • 13.10.4. Recent Developments
• 13.11. Abbott
  • 13.11.1. Company Overview
  • 13.11.2. Company Revenue
  • 13.11.3. Products
  • 13.11.4. Recent Developments
• 13.12. Cipla Inc.
  • 13.12.1. Company Overview
  • 13.12.2. Company Revenue
  • 13.12.3. Products
  • 13.12.4. Recent Developments
• 13.13. Gilead Sciences Inc.
  • 13.13.1. Company Overview
  • 13.13.2. Company Revenue
  • 13.13.3. Products
  • 13.13.4. Recent Developments
• 13.14. Biogen
  • 13.14.1. Company Overview
  • 13.14.2. Company Revenue
  • 13.14.3. Products
  • 13.14.4. Recent Developments
• 13.15. Organon Group of Companies
  • 13.15.1. Company Overview
  • 13.15.2. Company Revenue
  • 13.15.3. Products
  • 13.15.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies